Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock

子公司层面的投资为公司抗病毒知识产权组合的商业化提供资金，且不发行MGRX普通股

DALLAS, TEXAS, Oct. 01, 2026 (GLOBE NEWSWIRE) --

德克萨斯州达拉斯，2026年10月1日（环球电讯社）--

Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that its former wholly-owned subsidiary, MangoRx IP Holdings, LLC (“MangoRx IP”), has entered into subscription agreements with two strategic investors for an aggregate investment of $2.5 million directly into MangoRx IP, and has received the first tranche of $1.75 million due thereunder.

Mangoceuticals, Inc.（纳斯达克股票代码：MGRX）（“Mangoceuticals”或“公司”）是一家专注于通过旗下品牌 MangoRx 和 PeachesRx 的安全远程医疗平台开发、营销和销售健康与保健产品的公司。该公司今日宣布，其前全资子公司 MangoRx IP Holdings, LLC（“MangoRx IP”）已与两家战略投资者签署认购协议，获得对 MangoRx IP 的直接投资总额 250 万美元，并已收到根据该协议应付的首笔款项 175 万美元。

Importantly, the investments are being made at the subsidiary level and do not involve the issuance of any shares of Mangoceuticals common stock, warrants or other securities of the publicly-traded parent company. Accordingly, the transactions do not increase the number of outstanding shares of Mangoceuticals or otherwise impact the Company’s public capitalization structure..

重要的是，这些投资是在子公司层面进行的，不涉及发行上市公司母公司 Mangoceuticals 的任何普通股、认股权证或其他证券。因此，这些交易不会增加 Mangoceuticals 的流通股数量，也不会对公司的公开资本结构产生其他影响。

Under the terms of the agreements, the investors have committed to purchase an aggregate 25% membership interest in MangoRx IP for $2.5 million, payable in two tranches. The initial tranche consists of the equivalent of a 17.5% membership interest on a post-acquisition basis for $1.75 million, and the second tranche consists of the remaining 7.5% membership interest for $750,000, payable within 60 days following the initial closing, or by November 28, 2026, subject to the terms and conditions of the applicable subscription agreement..

根据协议条款，投资者承诺以250万美元购买MangoRx IP合计25%的成员权益，款项分两期支付。首期付款对应收购后17.5%的成员权益，金额为175万美元；第二期付款对应剩余7.5%的成员权益，金额为75万美元，须在首次交割完成后60天内或于2026年11月28日之前支付，具体须遵守适用认购协议的条款和条件。

We believe that the investment positions MangoRx IP to pursue opportunities across the full scope of its patent portfolio, which covers oral-surface administered preparations designed to help prevent illnesses acquired through the oral cavity and pharynx. In addition to poultry applications, we believe the technology has potential applications in livestock feed and water additives and in human oral-care formats, including toothpaste, mouthwash, lozenges, and oral sprays.

我们认为，此次投资使MangoRx IP能够充分利用其专利组合的全部范围来寻求发展机会，该专利组合涵盖经口腔表面给药的制剂，旨在帮助预防通过口腔和咽部获得的疾病。除了在家禽领域的应用外，我们认为该技术还潜在适用于牲畜饲料和水添加剂，以及人类口腔护理产品，包括牙膏、漱口水、润喉糖和口腔喷雾剂。

According to Fortune Business Insights, .

根据财富商业洞察（Fortune Business Insights）的数据，

the global oral care market was valued at approximately $34.8 billion in 2025

2025年，全球口腔护理市场估值约为348亿美元。

, and the

，以及

global feed additives market was valued at approximately $39.8 billion in 2025

2025年，全球饲料添加剂市场规模估值约为398亿美元。

. The Company believes both markets are seeing growing demand for natural, non-antibiotic solutions, and that this breadth of application, supported by granted and pending patents across major markets, gives MangoRx IP multiple paths to potential monetization.

. 本公司认为，这两个市场对天然、非抗生素解决方案的需求日益增长，并且这种广泛的应用范围，辅以在主要市场已获得和正在申请的专利支持，为 MangoRx IP 提供了多种潜在的货币化途径。

“We believe that this investment represents an important validation of the value we have built within MangoRx IP Holdings and provides us with additional capital to advance the next phase of commercialization, without issuing a single share of MGRX common stock,” said Jacob Cohen, Founder and Chief Executive Officer of Mangoceuticals.

Mangoceuticals 创始人兼首席执行官雅各布·科恩表示：“我们相信，这项投资是对我们在 MangoRx IP Holdings 中所创造价值的重要认可，并为我们提供了额外的资本，以推进下一阶段的商业化进程，且无需发行任何一股 MGRX 普通股。”

“We deliberately structured this investment at the subsidiary level to accomplish two key objectives: bring in strategic outside capital to help fund the commercialization of our intellectual property portfolio, while preserving the capital structure of Mangoceuticals and limiting dilution to our public shareholders.

“我们特意在子公司层面构建此项投资，以实现两个关键目标：引入战略外部资本，为本公司知识产权组合的商业化提供资金支持，同时保持Mangoceuticals的资本结构稳定，并限制对公众股东的股权稀释。”

We also believe that having strategic investors aligned with MangoRx IP further strengthens our position as we pursue potential licensing, distribution and other commercialization opportunities.”.

“我们还认为，拥有与MangoRx IP战略一致的投资者，在我们寻求潜在许可、分销和其他商业化机会时，将进一步巩固我们的地位。”

MangoRx IP owns the patent portfolio behind MGX-0024, the Company’s antiviral technology. The technology is protected in the U.S. under Patent No. 11,517,523, and corresponding national patents have been granted or are pending in the EU, Canada, China, India, Australia, and Japan.

MangoRx IP 拥有公司抗病毒技术 MGX-0024 背后的专利组合。该技术在美国受第 11,517,523 号专利保护，并在欧盟、加拿大、中国、印度、澳大利亚和日本已获得相应国家专利或正在申请中。

The membership interests have been, and will be, offered and sold in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506(b) of Regulation D. They have not been registered under the Securities Act or any state securities laws, and they may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

会员权益已并将根据经修订的《1933年证券法》第4(a)(2)条和/或D条例第506(b)条以私募方式发行和出售。这些权益未根据《证券法》或任何州证券法进行注册，除非进行注册或适用此类注册要求的豁免，否则不得在美国境内发行或出售。

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities..

本新闻稿不构成出售任何证券的要约，也不构成购买任何证券的要约邀请。

About Mangoceuticals, Inc.

关于芒果制药公司

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. The Company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management.

MangoRx 致力于通过安全的远程医疗平台开发各类男性健康与保健产品及服务。公司目前提供基于药物的产品，专门用于治疗勃起功能障碍、促进头发生长、激素替代疗法以及体重管理。

Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit .

有兴趣的消费者可以使用 MangoRx 的远程医疗平台，享受便捷的服务体验。处方请求将由持牌医疗提供者进行审核，一旦获批，将通过 MangoRx 的合作复方药房进行配药，并以私密方式直接配送至患者家门口。如需了解更多关于 MangoRx 的使命及其他产品信息，请访问 。

www.MangoRx.com

www.MangoRx.com

.

。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示性说明

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target,” “up to” or similar words or phrases.

本新闻稿中的某些陈述包含适用证券法律意义上的前瞻性信息，包括1995年《私人证券诉讼改革法》意义上的前瞻性信息（“前瞻性陈述”）。这些前瞻性陈述代表公司目前对未来事件的预期或信念，通常可以通过包含“估计”、“期望”、“预测”、“相信”、“ anticipated ”、“打算”、“计划”、“预见”、“预报”、“可能”、“将”、“目标”、“高达”等词语或类似词语或短语的陈述来识别。

These forward-looking statements include, but are not limited to, the timing and receipt of the second tranche of subscription funds discussed above, the use of the proceeds of the investments and the outcome thereof; the commercialization and monetization of MangoRx IP’s intellectual property; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; macroeconomic, industry and market conditions, including inflation, interest rate volatility, recessionary trends, financial market disruptions, changes in regulatory or political environments, and other factors beyond the Company’s control that could adversely affect its business, financial condition and results of operations; our ability to meet the continued listing requirements of Nasdaq and maintain the listing of our common stock on Nasdaq, including as a result of our current non-compliance with certain listing standards relating to our stock price; our ability to successfully undertake a crypto treasury strategy in the future; risks .

这些前瞻性陈述包括但不限于：上述第二批认购资金的到位时间及收取情况、投资资金的使用及其结果；MangoRx IP 知识产权的商业化与货币化；对战略交易的审查与评估及其对股东价值的影响；公司开展战略交易评估的流程；潜在未来战略交易的结果及其条款；宏观经济、行业和市场状况，包括通货膨胀、利率波动、衰退趋势、金融市场动荡、监管或政治环境的变化，以及可能对公司业务、财务状况和经营业绩产生不利影响的其他不可控因素；我们满足纳斯达克持续上市要求并维持普通股在纳斯达克上市的能力，包括因当前未能符合与股价相关的某些上市标准而导致的风险；我们未来成功实施加密资产储备策略的能力；风险。

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and subsequent reports.

有关可能影响公司财务结果的潜在因素的更多信息，不时包含在公司向美国证券交易委员会（SEC）提交的文件中的“关于前瞻性陈述的警示说明”、“风险因素”以及“管理层对财务状况和经营成果的讨论与分析”章节中，包括公司截至2025年12月31日止年度的10-K表年度报告、我们截至2026年6月30日止季度的10-Q表季度报告以及后续报告。

These filings are available at .

这些备案文件可在以下位置获取：

www.sec.gov

www.sec.gov

and at our website at

以及在我们的网站上

https://www.mangoceuticals.com/sec-filings

https://www.mangoceuticals.com/sec-filings

. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results.

所有随后归因于本公司或代表本公司行事的任何人的书面和口头前瞻性陈述，均明确以上述警示性声明为完整限定。其他未知或不可预测的因素也可能对本公司的未来业绩产生重大不利影响。

The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company.

本新闻稿中包含的前瞻性陈述仅截至本稿发布之日作出。本公司无法保证未来的业绩、活动水平、表现或成就。因此，您不应过度依赖这些前瞻性陈述。最后，除法律要求外，本公司没有义务在本新闻稿发布日后更新这些陈述，也没有义务更新或更正由第三方编制且非由本公司付费的信息。

If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements..

如果我们更新一项或多项前瞻性陈述，不得由此推断我们将就这些或其他前瞻性陈述进行额外更新。

FOR INVESTOR RELATIONS

投资者关系

Mangoceuticals Investor Relations

Mangoceuticals 投资者关系

Email:

电子邮件：

investors@mangorx.com

investors@mangorx.com